Wistar Institute Develops Long-Acting Weight-Loss Drug Lasting 70 Days in Mice

Researchers at the Wistar Institute report a novel formulation of a weight-loss drug that, in mouse trials, maintains efficacy for up to 70 days per dose—roughly ten times longer than current weekly injections like Ozempic. The mechanism reportedly turns the body into a sustained production site for the drug, but human applicability and safety remain unproven. This is an early-stage preclinical finding; no clinical trials or regulatory milestones are cited.